Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Advanced high-grade serous ovarian cancer.

HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy

    • Gynecology
    • Market & Medicine
    • Oncology
    • RX
    • Studies
  • 2 minute read

As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted in a substantial improvement in progression-free survival (PFS) with a consistent safety profile in the pivotal study.

As the fifth leading cause of cancer death in women, ovarian cancer remains a major therapeutic challenge today. The five-year survival rate is only about 45%, which is particularly due to the often already advanced stage at diagnosis. It is precisely those patients whose tumor is already FIGO stage III or IV and homologous recombination deficiency (HRD) at the time of detection who can now benefit from improved maintenance therapy. Thus, olaparib is now approved in Switzerland in combination with bevacizumab for this indication in high-grade serous ovarian cancer. The prerequisite is complete or partial remission following first-line chemotherapy combined with bevacizumab.

One in two women with advanced ovarian cancer suffers from an HRD-positive tumor. Homologous recombination deficiencies encompass a broad spectrum of genetic alterations, including BRCA mutations. All women with a BRCA mutation are HRD positive, but the BRCA mutation is not the only cause of homologous recombination deficiency. By expanding the first-line indication for olaparib beyond BRCA-positive tumors, Lynparza® can now be used in patients who have other genetic aberrations.

In the pivotal Phase III PAOLA-1 trial, a median progression-free survival of 37.2 months was observed with combination maintenance therapy with olaparib and bevacizumab, compared with 17.7 months with bevacizumab treatment alone. In HRD-positive advanced ovarian cancer, the risk of disease progression or death was reduced by 67% using combination therapy. While these results were already published in The New England Journal of Medicine in 2019, more interesting data were added at the 2020 European Society for Medical Oncology (ESMO) Virtual Annual Congress. Thus, the addition of olaparib to maintenance therapy showed benefit beyond the first disease progression and statistically significantly prolonged the duration to the second disease progression. This was delayed by a median of 15 months with the additional medication.

Of all PARP inhibitors, olaparib has the broadest and most advanced clinical development program. With the new approval extension, another important step has been taken in the treatment of ovarian cancer. We are looking forward to further results from the various studies.

Source: press release “Lynparza® (olaparib) in combination with bevacizumab approved in Switzerland for first-line maintenance therapy in advanced ovarian cancer with homologous recombination deficiency (HRD),” 1. December 2020, AstraZeneca AG, Baar, Switzerland and MSD Merck Sharp & Dohme AG, Lucerne.

 

Further reading:

  • Professional information Lynparza® on www.swissmedicinfo.ch, as of September 2020.
  • Ray-Coquard I, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019; 381: 2416-2428.
  • Gonzalez-Martin A, et al: Maintenance olaparib plus bevacizumab in patients with newly diagnosed, advanced high-grade ovarian carcinoma: final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial. Presented at ESMO Virtual Congress 2020, September 19-21. Abstract #LBA33, Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

 

InFo ONCOLOGY & HEMATOLOGY 2021; 9(1): 31.

Autoren
  • Med. pract. Amelie Stüger
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Maintenance therapy
  • ovarian cancer
  • Ovarian Cancer
  • PARP inhibitor
Previous Article
  • Heart failure

Effectively reduce re-hospitalization in patients with iron deficiency

  • Cardiology
  • Market & Medicine
  • RX
  • Studies
View Post
Next Article
  • Insomnia

When counting sheep doesn’t help: comprehensive therapy for sleep disorders

  • Congress Reports
  • General Internal Medicine
  • Neurology
  • Pharmacology and toxicology
  • Psychiatry and psychotherapy
  • RX
View Post
You May Also Like
View Post
  • 5 min
  • Vaccine-preventable respiratory diseases

RSV and pneumococci: recommendations for risk groups

    • Congress Reports
    • General Internal Medicine
    • Infectiology
    • Pediatrics
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 5 min
  • Circadian rhythm in asthma

Chronotherapy can improve control

    • Allergology and clinical immunology
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
View Post
  • 6 min
  • Update on diagnostics, risk stratification and therapy

Acute myeloid leukemia 2025

    • Education
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 4 min
  • New practice guideline for fibromyalgia syndrome

Good times, bad times

    • Congress Reports
    • General Internal Medicine
    • Neurology
    • Pharmacology and toxicology
    • Physical medicine and rehabilitation
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 5 min
  • Findings from the TRACK-FA study

Neuroimaging biomarkers in Friedreich’s ataxia

    • Genetics
    • Neurology
    • Pediatrics
    • RX
    • Studies
View Post
  • 12 min
  • Doing sport without fear or risk

Doing sport without fear or risk

    • CME continuing education
    • Endocrinology and Diabetology
    • Pediatrics
    • RX
    • Sports Medicine
View Post
  • 8 min
  • Chronic inducible urticaria

What has stayed the same, what has changed?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • National Health Report 2025

Mental health in Switzerland

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Doing sport without fear or risk
  • 2
    UV protection and skin cancer screening – Update 2025
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Yellow nail and Swyer-James syndrome
  • 5
    Diagnostic indications

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.